biocompatibility, fda and iso 10993
TRANSCRIPT
-
8/9/2019 Biocompatibility, FDA and ISO 10993
1/33
B iocompatib i l i ty, FDA and ISO 10993
Steven S. Saliterman, MD, FACPDepartment of Biomedical Engineering, University of Minnesotawww.tc.umn.edu/~drsteve
-
8/9/2019 Biocompatibility, FDA and ISO 10993
2/33
Steven S. Saliterman, MD, FACP
Medical Microdevices
Microni t, Galambos, Affymetrix,, Lifescan, Medtronic
-
8/9/2019 Biocompatibility, FDA and ISO 10993
3/33
Steven S. Saliterman, MD, FACP
Biocompatibility
Biocompatibility testing answers two
fundamental questions: Is the material safe?
Does it have the necessary physical andmechanical properties for its proposed function?
The extent to which a material needs to becharacterized depends on: Type of material,
End use of the device (is it a medical device?), Function of the material within the device.
Availability of existing data on the material.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
4/33
Steven S. Saliterman, MD, FACP
Biofouling Biofouling is the process whereby functioning of a
BioMEMS device is interfered with by the biologicalresponse of the host. This commonly occurs when macrophages and
foreign body giant cells (FBGCs) attach to theimplanted device, accumulate, grow and interfere
with normal operation. Surface coating of biomaterials seems one good
approach to lessen the inflammatory response,lessen macrophage adhesion and FBGCs growth,
and improve wound healing. The foreign body response by the host is largely
independent of the material’s being polymeric,ceramic or metallic; being hydrophobic orhydrophilic; or being hard or soft.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
5/33
Steven S. Saliterman, MD, FACP Voskerician, G., et al., Biomaterials 24(11), 2003
SEM photomicrographs showing fusion of macrophagesinto foreign body giant cells: Individual macrophage aggregation on silicon dioxide (day 7) (left).
Enlarging giant cell with fusion of cytoplasm and consolidation ofnuclei (day 14) (right).
Foreign Body Giant Cells
-
8/9/2019 Biocompatibility, FDA and ISO 10993
6/33
Steven S. Saliterman, MD, FACP
Biocompatibility needs to be considered at the onset of
design: Use known biocompatible materials.
Individual components as well as overall packaging areimportant.
Material testing is performed to determine toxicity ofthe material, leachable substances and degradationproducts.
The FDA relies on ISO 10993 Standard and has
additional recommended steps. Outsourcing testing may be required for most
institutions and companies.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
7/33
Steven S. Saliterman, MD, FACP
ISO Definition of a Medical Device
Any instrument, apparatus, appliance, material
or other article, including software, whetherused alone or in combination, intended by themanufacturer to be used for human beingssolely or principally for the following purposes:
Diagnosis, prevention, monitoring, treatment oralleviation of disease;
Diagnosis, monitoring, treatment, alleviation of orcompensation for an injury or handicap;
Investigation, replacement or modification of theanatomy or of a physiological process;
Control of conception.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
8/33
Steven S. Saliterman, MD, FACP
The ISO 10993 Standard
The ISO 10993 International Standard pertains
to: Surface devices on the skin, mucosal membranes,
breached or compromised surfaces.
External communicating devices with blood, tissue,bone, dentin.
Implantable devices.
Its purpose is to protect humans and to serveas a framework for selecting tests to evaluate
biological responses. In so doing consideration has been given to
minimize the number and exposure of testanimals.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
9/33
Steven S. Saliterman, MD, FACP
Flowchart for Biocompatibility
Subparts ISO 10993 & FDA Evaluation Tests
Not all medical devices require ISO 10993
testing, including the following: Lab-on-a-chip (LOC) devices,
Micro total chemical analysis systems (µTAS) usedin laboratory instrumentation,
Point-of-care systems or hand-held devices that donot contact or penetrate the skin,
MEMS devices used in medical imaging machines.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
10/33
Steven S. Saliterman, MD, FACP
Characterization Methods Identification of a materials constituents and:
Changes of the material over time, Changes with exposure to different environments,
Lot-to-lot consistency for manufacturing purposes.
Methodologies: Infrared spectral analysis (IR), Thermal analysis,
Density analysis,
Molecular weight distribution,
Mechanical properties,
Surface properties,
Extract Characterization.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
11/33
Steven S. Saliterman, MD, FACP
Infrared Spectral Analysis (IR)
Albert, DE, Medical Device Technology,
Octo Media Ltd, June 2004
-
8/9/2019 Biocompatibility, FDA and ISO 10993
12/33
Steven S. Saliterman, MD, FACP
Purified Water Extracts
Albert, DE, Medical Device Technology,
Octo Media Ltd, June 2004
-
8/9/2019 Biocompatibility, FDA and ISO 10993
13/33
Steven S. Saliterman, MD, FACP
Isopropyl Alcohol Extracts
Albert, DE, Medical Device Technology,
Octo Media Ltd, June 2004
-
8/9/2019 Biocompatibility, FDA and ISO 10993
14/33
Steven S. Saliterman, MD, FACP
Cytotoxicity
Cytotoxicity refers to cell damage caused by
materials, either by direct contact or byleachable substances (extracts).
Cell damage may occur by a variety of means
including activation of the complement system. The complement system involves a number of
serum factors that are activated in the presence of
antigen-antibody binding, bacteria and viruses, or
foreign materials.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
15/33
Steven S. Saliterman, MD, FACP
Mouse Fibroblast Cells
Normal Cytotoxicity
Image Courtesy of NAMSA
-
8/9/2019 Biocompatibility, FDA and ISO 10993
16/33
Steven S. Saliterman, MD, FACP
Sensitization
Sensitization refers to a materials ability to
induce specific delayed-type hypersensitivity inthe body upon initial exposure:
Haptens,
Langerhans cells and T-cell lymphocytes, Lymphokines.
Testing:
Guinea pig maximization test (GPMT), Closed-patch test (Buehler test),
Murine Local Lymph Node Assay.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
17/33
Steven S. Saliterman, MD, FACP
Guinea Pig Maximization Test
-
8/9/2019 Biocompatibility, FDA and ISO 10993
18/33
-
8/9/2019 Biocompatibility, FDA and ISO 10993
19/33
Steven S. Saliterman, MD, FACP
Dermal Irritation
-
8/9/2019 Biocompatibility, FDA and ISO 10993
20/33
Steven S. Saliterman, MD, FACP
Systemic Toxicity Systemic toxicity (body at large):
Acute toxicity - within 24 hours, Subacute toxicity - single dose or multiple
doses of a test sample during a period from 14to 28 days,
Subchronic toxicity - at 90 days, but notexceeding 10% of the life cycle of the device,
Chronic toxicity - single or multiple exposures
to medical devices, materials and extractsduring at least 10% of their lifespan of the testanimal.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
21/33
Steven S. Saliterman, MD, FACP
Genotoxicity, Carcinogenicity and
Reproduction
Genotoxicity - DNA damage to somatic cells
and second generation effects throughdamage to germ cells.
Carcinogenicity toxicity – observation of testanimals for a major portion of their life span for
development of cancer. This observation mayoccur during or after exposure to testsubstances.
Reproductive toxicity - reproduction, fertility
and teratogenicity (the ability to cause birthdefects).
-
8/9/2019 Biocompatibility, FDA and ISO 10993
22/33
Steven S. Saliterman, MD, FACP
Genotoxicity
Gene or point mutations, small deletions,
mitotic recombination or microscopicallyvisible chromosome changes.
Studies available:
Ames bacterial reverse mutation assay,
Mouse lymphoma assay,
Chinese hamster ovary cells, Mouse bone marrow micronucleus test.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
23/33
Steven S. Saliterman, MD, FACP Image Courtesy of NAMSA
-
8/9/2019 Biocompatibility, FDA and ISO 10993
24/33
Steven S. Saliterman, MD, FACP
Implantation
Tests for assessment of the local
effects of implant material on livingtissue.
Comparison is made with reactions
observed to medical devices whoseclinic acceptability has already beenestablished.
Short term vs. long term studies.Solid vs. non-solid materials.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
25/33
Steven S. Saliterman, MD, FACP
Histological Changes
Image Courtesy of NAMSA
-
8/9/2019 Biocompatibility, FDA and ISO 10993
26/33
Steven S. Saliterman, MD, FACP
Hemocompatibility
Hemocompatiblity tests evaluate the
effects of medical devices or materialsthat are in contact (or indirect contact)
with blood, on blood components.
Hemolysis is the abnormal breakdown of
blood cells.
Thrombosis is the clotting of blood with
obstruction of a blood vessel and potential
for embolization.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
27/33
Steven S. Saliterman, MD, FACP
Toxin Exposure
Normal Red and White Blood Cells White Blood Cell Karyorrhexis
Image Courtesy of NAMSA
-
8/9/2019 Biocompatibility, FDA and ISO 10993
28/33
Steven S. Saliterman, MD, FACP
Degradation
Degradation is the unwanted breakdown
of implanted BioMEMS materials. Ideally in an implanted device all
materials of degradation are ultimately
removed by the body without toxicity.
Polymer degradation.
Ceramic degradation. Metal and alloy electrochemical effects,
-
8/9/2019 Biocompatibility, FDA and ISO 10993
29/33
Steven S. Saliterman, MD, FACP
Polymer Degradation
Chemical bond scission due to hydrolytic and
oxidative processes. Enzymes, proteins and other cellular activity
can alter the rate and nature of degradation.
Ultraviolet cleavage of chemical bonds. Gamma and electron radiation that cause
embrittlement, discoloration and thermalinstability.
Metal induced degradation from impurities,additives or hybrid construction
-
8/9/2019 Biocompatibility, FDA and ISO 10993
30/33
Steven S. Saliterman, MD, FACP
Biocompatibility of Polymers
Properties of polymers that determine theirbiocompatibility through protein absorption,cell adhesion, cytotoxicity, blood compatibility,and tissue compatibility include: Interfacial free energy,
Balance between hydrophilicity and hydrophobicityon the surface,
Chemical structure and functional groups,
The type and density of surface charge,
Molecular weight of the polymer, Conformational flexibility of the polymer,
Surface topography and roughness.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
31/33
-
8/9/2019 Biocompatibility, FDA and ISO 10993
32/33
Steven S. Saliterman, MD, FACP
Summary
Biocompatibility testing answers two
fundamental questions: Is the material safe?
Does it have the necessary physical andmechanical properties for its proposed function?
Biofouling is the process whereby functioningof a BioMEMS device is interfered with by thebiological response of the host.
The ISO 10993 Standard is to protect humansand to serve as a framework for selecting teststo evaluate biological responses.
-
8/9/2019 Biocompatibility, FDA and ISO 10993
33/33
Steven S. Saliterman, MD, FACP
ISO 10993 Subparts discussed:
Characterization Cytotoxicity
Sensitization
Irritation System Toxicity
Genotoxicity
Implantation Hemocompatibility
Degradation